Cargando…
WITHDRAWN: Incidence and mortality of COVID-19 in Iranian multiple sclerosis patients treated with disease-modifying therapies
This article has been withdrawn at the request of the authors and editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.
Autores principales: | Etemadifar, M., Aghababaee, A., Sedaghat, N., Rayani, M., Nouri, H., Abhari, A., Salari, M., Majdinasab, N., Ghiasian, M., Bayati, A., Nabavi, S.M., Mansouri, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492065/ https://www.ncbi.nlm.nih.gov/pubmed/33039152 http://dx.doi.org/10.1016/j.neurol.2020.08.001 |
Ejemplares similares
-
COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?
por: Etemadifar, Masoud, et al.
Publicado: (2021) -
Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2023) -
Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
por: Etemadifar, Masoud, et al.
Publicado: (2022) -
Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study
por: Etemadifar, Masoud, et al.
Publicado: (2022) -
Association of COVID-19 with Disability Progression and Disease Exacerbation in People with Relapsing-Remitting Multiple Sclerosis: Evidence from a Year-Long Observational Study
por: Sedaghat, Nahad, et al.
Publicado: (2022)